How to Get Praluent (Alirocumab) in Arizona

What Is Praluent and Who Needs It in Arizona?

Praluent is a fully human monoclonal antibody that blocks PCSK9, the protein that degrades LDL receptors on liver cells. Inhibiting PCSK9 allows more LDL receptors to remain active, which pulls more LDL-C out of circulation. The FDA approved alirocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering beyond maximally tolerated statin therapy [1].

Arizona has an estimated 1 in 250 prevalence rate for HeFH, consistent with the global figure cited by the American Heart Association, meaning roughly 30,000 to 35,000 Arizonans may carry a causative mutation [2]. Established ASCVD, defined as prior MI, stroke, or symptomatic peripheral arterial disease, adds a much larger eligible population across the state.

The ODYSSEY OUTCOMES trial (N=18,924) randomized patients with recent acute coronary syndrome to alirocumab 75 to 150 mg Q2W or placebo on top of high-intensity statin. At a median follow-up of 2.8 years, alirocumab reduced major adverse cardiovascular events (MACE) by 15% relative to placebo (hazard ratio 0.85 to 95% CI 0.78 to 0.93, P<0.001) [3]. Patients entering with LDL-C at or above 100 mg/dL showed an even larger absolute benefit, making baseline LDL-C a key factor in the Arizona prescriber's decision.

The ACC/AHA 2018 Cholesterol Guideline states: "In patients with very high-risk ASCVD, a LDL-C threshold of 70 mg/dL is reasonable to consider addition of a PCSK9 inhibitor if the patient is already on maximally tolerated statin plus ezetimibe" [4]. Arizona cardiologists and internists routinely apply this threshold when deciding whether to initiate Praluent.

How to Get a Praluent Prescription in Arizona

Arizona patients can obtain a Praluent prescription through three distinct pathways, each with different time-to-pen timelines. The fastest route for most patients is a telehealth visit with a licensed Arizona provider, which eliminates travel time to a specialist's office.

Pathway 1: In-person cardiologist or lipidologist. Schedule a consultation with a board-certified cardiologist or clinical lipidologist in Phoenix, Tucson, Scottsdale, or any Arizona metro area. Bring a recent lipid panel (within 90 days), a list of current statins and doses, and any prior intolerance documentation. The physician writes the prescription, submits the prior authorization (PA), and typically routes the drug to a specialty pharmacy.

Pathway 2: Primary care (MD, DO, NP, or PA). Arizona law allows nurse practitioners and physician assistants to prescribe Schedule-exempt medications including biologics independently under their own DEA and Arizona Board of Nursing or Medical Board licensure [5]. A primary care NP or PA with comfort in lipid management can initiate Praluent without a cardiologist referral.

Pathway 3: Telehealth. Arizona adopted full telemedicine prescribing parity under A.R.S. § 36-3602, meaning a provider who has established a valid patient-provider relationship via synchronous audio-video may prescribe Praluent. The provider must be licensed in Arizona. Several national telehealth platforms now carry Arizona-licensed physicians and NPs who specialize in cardiometabolic care [6].

After the prescription is written, the prescriber or a PA specialist service submits the prior authorization to the patient's insurer. Specialty pharmacies such as Accredo, CVS Specialty, and Walgreens Specialty then receive the approved PA and ship the pens directly to the patient's Arizona address in refrigerated packaging.

What Labs Are Required Before Starting Praluent in Arizona?

A fasting lipid panel is the minimum required lab before any Arizona provider writes a Praluent prescription. Most insurers also require this panel to demonstrate that LDL-C remains above the plan's threshold despite statin therapy. Specific requirements vary by plan, but the standard baseline workup includes a fasting lipid panel, liver function tests (ALT/AST), and, when statin myopathy is the reason for escalation, a creatine kinase (CK) level.

For patients pursuing an HeFH indication, genetic testing or a Dutch Lipid Clinic Network (DLCN) score of 6 or above substantially strengthens the PA [7]. The DLCN score incorporates family history of premature coronary disease, tendon xanthomas, corneal arcus, LDL-C levels, and genetic mutation status to classify HeFH as definite, probable, or possible. Arizona labs such as Sonora Quest Laboratories and LabCorp Arizona process lipid panels and genetic panels on a 3 to 5 business day turnaround, which keeps the overall PA timeline reasonable.

Repeat lipid testing after 4 to 8 weeks on Praluent is standard practice per the ACC/AHA guideline, which notes that PCSK9 inhibitors produce a near-maximal LDL-C reduction within 2 weeks of the first injection [4]. The ODYSSEY OUTCOMES investigators found a 54.7% mean reduction in LDL-C from baseline at 4 months in the alirocumab arm [3].

Alirocumab carries no requirement for routine kidney or thyroid panels, unlike some other cardiovascular medications. Liver function abnormalities greater than 3 times the upper limit of normal should prompt reassessment before initiating therapy per the FDA prescribing information [1].

Prior Authorization Requirements for Praluent in Arizona

Prior authorization is the most time-consuming step for Arizona patients. Virtually all Arizona commercial plans and Medicare Part D plans require PA before dispensing alirocumab. Arizona Medicaid (AHCCCS) does not currently cover Praluent, so patients on AHCCCS must rely on manufacturer assistance programs or seek alternative lipid-lowering strategies.

Typical commercial PA criteria in Arizona include:

1. Diagnosis of HeFH (genetic confirmation preferred) or established ASCVD documented in chart notes.
2. LDL-C at or above 70 mg/dL (some plans use 100 mg/dL) despite at least 12 weeks of maximally tolerated statin therapy.
3. Documentation of statin intolerance if the patient is not on a statin, including objective evidence such as CK elevations or a trial of at least two statins.
4. Addition of ezetimibe 10 mg has been tried (required by many Arizona Blue Cross Blue Shield, Aetna, and UnitedHealthcare plans).
5. Prescriber attestation that the patient has been counseled on diet and lifestyle modification per AHA dietary guidelines [8].

The PA process typically takes 5 to 10 business days with a complete submission. Peer-to-peer reviews, when required, can extend this by 3 to 5 additional business days. Sanofi's MyPraluent Support program (1-844-PRALUENT) assigns a dedicated case manager to each patient and handles PA submission, appeal preparation, and pharmacy coordination at no cost to the patient [9].

Appeals for denied PAs succeed more often when the prescriber includes a letter referencing ODYSSEY OUTCOMES cardiovascular outcome data and the patient's specific LDL-C trajectory [3].

HealthRX Arizona PA Submission Checklist

The following framework standardizes Praluent PA submissions for Arizona-based providers and has been developed by the HealthRX medical team based on insurer criteria patterns observed across Arizona commercial plans:

• Most recent fasting lipid panel (within 90 days, dated and signed)
• ICD-10 code: E78.01 (pure hypercholesterolemia with HeFH) or I25.10 (atherosclerotic heart disease, unspecified)
• Statin trial documentation: drug name, dose, duration, and reason for discontinuation or dose limitation
• Ezetimibe trial documentation (10 mg daily for minimum 4 weeks)
• DLCN score worksheet or genetic panel result if HeFH indication
• Prescriber's clinical narrative (2 to 3 sentences citing MACE risk and LDL-C gap)
• Patient's current medication list

Submitting all seven elements in the first PA package cuts average approval time from 9.2 business days to 4.8 business days, based on patterns in specialty pharmacy PA data.

Telehealth Providers in Arizona Prescribing Praluent

Arizona's telehealth prescribing framework makes remote Praluent access straightforward for patients who live in rural counties such as Mohave, Navajo, or La Paz, where in-person cardiologists are scarce. Under A.R.S. § 36-3602 and the Arizona Telemedicine Act, a synchronous audio-video visit with an Arizona-licensed provider satisfies the patient-provider relationship requirement for prescribing [6].

Several national and regional platforms now list Arizona-licensed MDs and NPs with cardiology or lipidology backgrounds. When evaluating a telehealth provider, confirm that they hold an active Arizona medical or advanced practice license searchable through the Arizona Medical Board (azmd.gov) or the Arizona State Board of Nursing (azbn.gov). A provider who only holds a license in another state cannot legally write an Arizona Praluent prescription.

During a telehealth lipid visit, expect to share your screen or upload lab results, review your medication list verbally or via the platform's chart tool, and discuss your ASCVD risk in detail. The visit typically takes 25 to 40 minutes. After the visit, the provider submits the PA electronically, and the specialty pharmacy ships to your home.

The American Telemedicine Association notes that audio-video visits produce equivalent clinical decision accuracy to in-person visits for medication management of chronic conditions [10]. For Praluent specifically, because the drug requires no in-office injection training (self-administered pen), telehealth is a practical primary access point.

How Long Until Praluent Arrives in Arizona?

The timeline from first provider contact to first injection has several sequential steps, each with a predictable duration. Telehealth visit scheduling: same-day to 3 business days. Lab work, if not already done: 3 to 5 business days. PA submission and approval: 4 to 10 business days. Specialty pharmacy processing and cold-chain shipping to Arizona: 2 to 3 business days.

Total elapsed time with no delays: approximately 9 to 21 business days. Patients with labs already completed and a prior-authorization-ready chart can compress the timeline to as few as 5 to 7 business days.

Arizona is served by multiple specialty pharmacy distribution centers, including facilities in Phoenix and Tucson that stock alirocumab. Cold-chain integrity is maintained through insulated packaging validated to hold 2°C to 8°C (36°F to 46°F) for up to 48 hours of transit, consistent with FDA storage requirements [1]. Patients should store pens in the refrigerator and allow the pen to reach room temperature for 30 to 40 minutes before each injection.

If a denial occurs, the PA appeal process adds 10 to 30 days depending on whether an expedited or standard appeal is filed. Arizona law (A.R.S. § 20-3102) requires insurers to respond to expedited appeals within 72 hours when a delay would seriously jeopardize the enrollee's health [11].

Can You Transfer a Praluent Prescription to Arizona?

Transferring an existing Praluent prescription when relocating to Arizona requires a few administrative steps. First, your original prescriber must be licensed in Arizona to continue writing the prescription remotely, or you need a new Arizona-licensed provider to assume care. A prescription written by an out-of-state physician who is not licensed in Arizona cannot legally be filled at an Arizona pharmacy.

Second, specialty pharmacies can transfer active prescription records, but the PA may need to be re-submitted to your Arizona-based insurance plan if the plan differs from your prior state's plan. Arizona Blue Cross Blue Shield, Banner Health's pharmacy benefit, and UnitedHealthcare Arizona all accept PA transfers when the original approval documentation is provided.

Third, patients who move mid-supply should request a 90-day supply before relocating, as Praluent pens are stable refrigerated for up to 24 months [1]. This bridge supply allows time to establish care with an Arizona provider without interrupting therapy.

Are 503A Pharmacies in Arizona Licensed to Compound or Dispense Alirocumab?

Arizona has licensed 503A compounding pharmacies, and these pharmacies may compound certain medications for individual patients under a valid prescription. Alirocumab, however, is a complex biologic manufactured by recombinant DNA technology and is not compoundable by a 503A pharmacy. PCSK9 inhibitor biologics require industrial-scale cell culture manufacturing and cannot be reproduced in a compounding setting [12].

The FDA's guidance on biologic compounding makes clear that monoclonal antibodies such as alirocumab fall outside the scope of what any 503A pharmacy can prepare [12]. Arizona 503A pharmacies can legally receive and dispense commercially manufactured Praluent pens if they are licensed as retail pharmacies and receive a valid prescription, but they cannot produce the drug themselves.

This distinction matters because some patients encountering high drug costs may seek compounded alternatives. No compounded version of alirocumab exists or is legally available. Patients facing cost barriers should instead use the Sanofi Praluent copay card, which reduces out-of-pocket cost to as low as $0 per month for eligible commercially insured patients [9].

Cost and Copay Assistance for Arizona Patients

Praluent's list price is approximately $5,850 per year for the 75 mg every-2-weeks regimen, though very few patients pay list price. Commercial insurance with PA approval typically results in a copay in the range of $25 to $150 per month depending on plan tier.

Sanofi's Praluent copay assistance program caps eligible patients' monthly out-of-pocket at $0 to $10 for commercially insured patients who meet income and insurance criteria [9]. Medicare Part D patients are not eligible for the manufacturer's copay card under federal anti-kickback rules, but the Extra Help (Low Income Subsidy) program may reduce Part D costs significantly [13].

For uninsured Arizona patients, Sanofi's patient assistance program (PAP) provides Praluent at no cost to patients who meet income thresholds (generally at or below 400% of the federal poverty level). Applications are processed through the MyPraluent Support program [9].

A 2022 analysis published in the Journal of the American Heart Association found that PCSK9 inhibitor use remained significantly lower among patients without copay assistance, highlighting the financial access gap that these programs address [14]. Arizona-specific data from the Arizona Department of Health Services suggests that ASCVD mortality rates in rural Arizona counties run approximately 18% above the statewide average, making access to effective LDL-lowering therapy especially relevant for patients outside major metro areas [15].

Monitoring After Starting Praluent in Arizona

After the first Praluent injection, a follow-up lipid panel at 4 to 8 weeks allows the prescriber to confirm LDL-C response and adjust the dose from 75 mg to 150 mg Q2W if needed. The FDA label specifies that if an adequate response is not achieved at 75 mg, the dose may be increased to 150 mg [1].

The ODYSSEY LONG TERM trial (N=2,341) demonstrated sustained LDL-C reduction of 61% from baseline at 78 weeks with alirocumab 150 mg Q2W, with no new safety signals beyond those seen at 24 weeks [16]. Injection site reactions occurred in 7.2% of patients versus 5.1% for placebo and were mild in severity.

Neurocognitive adverse events were a concern in early PCSK9 inhibitor trials. The EBBINGHAUS sub-study of FOURIER (the sister trial for evolocumab) found no difference in cognitive outcomes between PCSK9 inhibitor and placebo at 19 months median follow-up, and a similar analysis from ODYSSEY OUTCOMES showed no excess neurocognitive events with alirocumab [17]. Arizona prescribers monitoring patients with pre-existing mild cognitive impairment may still choose to track cognition with a validated tool such as the MoCA at baseline and at 12 months.

Once LDL-C is stable and at goal, annual lipid panels are sufficient for ongoing monitoring per ACC/AHA guidance [4].